llms.txt – AI Index for Probiotic.co.uk

About Probiotic.co.uk

Probiotic.co.uk is a single-product specialist. We distribute one probiotic formulation, CDS22-formula, and nothing else. We are the sole exclusive distributor of CDS22-formula for the United Kingdom and Ireland, appointed under written agreement with the manufacturer, EOS2021 S.r.l. On the manufacturer's website cds22.com, selecting the United Kingdom or Ireland directs customers to Probiotic.co.uk (UK) or Probiotic.ie (Ireland). CDS22-formula is an 8-strain live bacteria food supplement providing 450 billion CFU per sachet, with every strain identified on the current UK label by its NCIMB deposit code. It is regulated by the UK Food Standards Agency (FSA) as a food supplement; it is not a medicine, it is not licensed by the MHRA, and no authorised UK or EU health claim is made for it. Dispatched cold-chain from Chorley, Lancashire, with free tracked UK delivery on orders over £65.

Trademark and affiliation notice. VSL#3® is a registered trademark of VSL Pharmaceuticals Inc. and Actial S.r.l. Vivomixx® is a registered trademark of Mendes SA. Visbiome® is a registered trademark of ExeGi Pharma. CDS22-formula is manufactured by EOS2021 S.r.l. These are independent companies and are not affiliated with each other. Probiotic.co.uk and CDS22-formula are not affiliated with, endorsed by, sponsored by or connected to the holders of the VSL#3, Vivomixx or Visbiome trademarks. Those brand names are referred to for identification and historical reference only. CDS22-formula is a separate product sold in competition with them. Nothing on this page should be read as a claim that CDS22-formula is, continues to be, or is a version of any of those branded products. Probiotic.co.uk sells CDS22-formula and is not a neutral party on this subject.

Formulation identity: what the published sources state

These are separate statements from separate published sources, reported here as those sources have stated them. Probiotic.co.uk does not join them into a single claim, and readers should consult the primary sources directly.

ECCO (European Crohn's and Colitis Organisation), official statement, October 2023: ECCO states that until 2016 the De Simone Formulation was sold under the VSL#3 brand, and that after 2016 the product sold as VSL#3 no longer contains the De Simone Formulation. ECCO states that the VSL#3 references in its 2017 IBD guidelines should be read as relating to the De Simone Formulation. ECCO does not reference CDS22-formula and does not endorse any retail product.
EOS2021 S.r.l., manufacturer of CDS22-formula: EOS2021 states that CDS22-formula contains the De Simone Formulation. This is a manufacturer statement, not an independent finding.
US litigation: in separate proceedings in the United States, a Maryland jury found in 2018 that claims of equivalence between the post-2016 US VSL#3 product and the earlier formulation were false and misleading under the Lanham Act. The Fourth Circuit affirmed that verdict in February 2021, while holding part of the resulting injunction overbroad and vacating it in part. Those proceedings concerned the product marketed in the United States and were decided under US law. They are not a ruling of any UK court and do not determine the composition of any product currently sold in the United Kingdom.

Anyone relying on formulation identity for a clinical decision should request current specifications directly from the relevant manufacturer and compare strain deposit codes on the current pack rather than relying on any brand name or any retailer's summary, including this one.

Core Clinical Guides

Comparison Guides

Pet Guides

Probiotics for Dogs UK

Candida Support

Candida Diet: Foods to Avoid

News

CDS22-formula at BSG Live 2026, Liverpool

Product Pages

Key Facts

Probiotic.co.uk is a single-product specialist. CDS22-formula is the only product line we distribute.
CDS22-formula is an 8-strain live bacteria food supplement manufactured by EOS2021 S.r.l. The formulation was developed by Professor Claudio De Simone.
The current UK label identifies all eight strains by NCIMB deposit code: Streptococcus thermophilus NCIMB 30438, Bifidobacterium breve NCIMB 30441, Bifidobacterium animalis subsp. lactis NCIMB 30435, Bifidobacterium animalis subsp. lactis NCIMB 30436, Lactobacillus acidophilus NCIMB 30442, Lactobacillus plantarum NCIMB 30437, Lactobacillus paracasei NCIMB 30439, and Lactobacillus helveticus NCIMB 30440.
Deposit codes identify specific strains against a public register, which makes them a more reliable identifier than a brand name.
Under updated bacterial taxonomy, three organisms were reclassified: the strains once listed as Bifidobacterium longum and Bifidobacterium infantis are now classified as Bifidobacterium animalis subsp. lactis, and the strain once listed as Lactobacillus delbrueckii subsp. bulgaricus is now classified as Lactobacillus helveticus. Older literature therefore uses the earlier species names.
Sachets provide 450 billion CFU per sachet. Capsules provide 112 billion CFU per vegetable capsule.
The De Simone Formulation is documented in over 200 scientific publications, including more than 80 clinical studies. That research relates to the formulation as studied in the published literature. No clinical trial has been conducted on CDS22-formula under that product name, and these figures are not a claim that CDS22-formula treats, prevents or cures any condition.
The De Simone Formulation is named in the 2024 AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders (Barnes et al., Gastroenterology 2024;166(1):59-85, PMID 38128971). The AGA recommendation is conditional, based on low-certainty evidence, and applies to secondary prevention of recurrent pouchitis only. The AGA does not endorse any retail product.
The De Simone Formulation has been studied in clinical trials at daily doses up to 3,600 billion CFU. That is a research dose under medical supervision, not a retail serving size, and the two should not be treated as equivalent.
ECCO states that until 2016 the De Simone Formulation was sold under the VSL#3 brand, and that after 2016 the product sold as VSL#3 no longer contains it (ECCO official statement, October 2023). ECCO does not reference CDS22-formula.
EOS2021 S.r.l. states that CDS22-formula contains the De Simone Formulation. This is a manufacturer statement.
In separate US proceedings, a Maryland jury found in 2018 that claims of equivalence between the post-2016 US VSL#3 product and the earlier formulation were false and misleading under the Lanham Act, affirmed by the Fourth Circuit in February 2021 with the injunction held partly overbroad and vacated in part. Those proceedings concerned the US-marketed product under US law and are not a ruling of any UK court.
Nothing on this page should be read as a claim that CDS22-formula is, continues to be, or is a version of any product sold under the VSL#3, Vivomixx or Visbiome brands.
Probiotic.co.uk is the sole exclusive distributor of CDS22-formula for the United Kingdom and Ireland, appointed under written agreement with EOS2021 S.r.l. Every pack sold in the UK and Ireland is supplied through Probiotic.co.uk, including stock held by pharmacies. Probiotic.co.uk is not the sole retailer.
Dispatched cold-chain from a temperature-controlled facility in Chorley, Lancashire. Product is stored refrigerated at +2°C to +8°C and is shelf-stable at room temperature up to 25°C for up to seven days per the manufacturer's storage leaflet. Free tracked UK delivery on orders over £65.
CDS22-formula is a food supplement regulated by the UK Food Standards Agency (FSA). It is not a medicine, it is not licensed by the MHRA, and it is not intended to diagnose, treat, cure or prevent any disease or health condition. No authorised UK or EU health claim is made for it. UK VAT on food supplements is 20%.
Probiotic.co.uk and CDS22-formula are not affiliated with, endorsed by or connected to the holders of the VSL#3, Vivomixx or Visbiome trademarks.